David Morcos, DO
Family Medicine · Monticello, NYNPI 1073889978
Payments from drug & device makers
Across 76 payments — averaging $19.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$505
- AbbVie$316
- Novo Nordisk$234
- GSK$103
- Boehringer Ingelheim$85
- Otsuka America Pharmaceutical, Inc.$66
- plus $167 from 7 others
What the payments were for
- Food & beverage$1,476100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 28 | $505 |
| AbbVie | 18 | $316 |
| Novo Nordisk | 8 | $234 |
| GSK | 6 | $103 |
| Boehringer Ingelheim | 4 | $85 |
| Otsuka America Pharmaceutical, Inc. | 4 | $66 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Johnson & Johnson | 1 | $27 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Novartis | 1 | $26 |
| Merck | 1 | $19 |
| Bayer | 1 | $19 |
| Astellas Pharma US Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tresiba$125
How this compares
$1,476 in reported general payments places this provider in the 70th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 70 | $85,372 |
| EliquisApixaban | 60 | $55,509 |
| XareltoRivaroxaban | 24 | $24,472 |
| JardianceEmpagliflozin | 20 | $20,453 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $18,169 |
| TrulicityDulaglutide | 15 | $16,383 |
| FarxigaDapagliflozin Propanediol | 17 | $12,097 |
| Spiriva RespimatTiotropium Bromide | 15 | $11,865 |
| MyrbetriqMirabegron | 15 | $11,658 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $10,412 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 192 | $8,766 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $8,748 |
| LinzessLinaclotide | 16 | $8,315 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $6,056 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 35 | $5,195 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $234 | $85,37270 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $85 | $32,31835 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $103 | $28,76948 claims |
| Johnson & JohnsonXarelto | $27 | $24,47224 claims |
| AstraZenecaFarxiga, Symbicort | $505 | $20,84445 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $11,65815 claims |
| MerckJanumet | $19 | $10,41215 claims |
| AbbVieLinzess | $316 | $8,31516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,321 family medicine providers in New York.
Other family medicine in Monticello
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.